Research summary

Spinocerebellar Ataxia

Authors of report
Jenish Bhandari, Pawan K Thada, and Debopam Samanta
Date of report
Medical conditions
Ataxia

The medical report focuses on Spinocerebellar Ataxia (SCA), a rare, inherited, progressive neurodegenerative disease that primarily affects the cerebellum. The condition is characterized by the absence of voluntary muscle coordination, which impacts gait stability, eye movement, and speech. The report emphasizes the heterogeneity of SCA, both genotypically and phenotypically, making it a complex disease to understand. SCA is a subset of hereditary cerebellar ataxia and is categorized based on distinct genetic loci. Over 40 different genetic types of SCAs have been identified so far. The report mentions that SCA1 was the first subtype to be described, and subsequent subtypes have been identified sequentially. Importantly, the report notes that SCA is not strictly confined to the cerebellum and spinal cord; it can also involve other parts of the central nervous system, such as pontine nuclei, spinal cord, peripheral nerves, cortex, and basal ganglia. The report highlights well-defined and common types of SCA, including SCA1, SCA2, SCA3, and SCA6, which account for more than half of all cases. Other rare variants make up the remaining cases. Interestingly, SCA6 is restricted to the cerebellum, while SCA2 spares it. The complexity of SCA is emphasized, particularly in understanding all its variants. The report suggests that the disease is challenging to describe comprehensively due to its complex nature, both at the genetic and phenotypic levels. The authors of the report, Jenish Bhandari, Pawan Thada, and Debopam Samanta, declare no relevant financial relationships with ineligible companies, ensuring the integrity of the study. In summary, the report provides a detailed overview of Spinocerebellar Ataxia, emphasizing its complexity and heterogeneity. It serves as a valuable resource for understanding the genetic and phenotypic variations of this rare, progressive neurodegenerative disease.

This is a summary of independent research published elsewhere. It is not a report of Beike treatment outcomes.

Free consultation

Speak with a medical advisor

No obligation. We’ll review your situation and respond within 48 hours.

  • Response within 48 hours from a medical advisor.
  • Confidential — your information stays with our medical team.
  • No cost, no obligation. We review your case and respond.

Reviewed by the Beike medical advisory team — answering patient inquiries since 2005.

If your diagnosis is not listed, please select 'other'.

Internationally accredited

Held to global laboratory and biologics standards.